TrialInternational journal of cancer2026

Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.

Anna E Nordenskjöld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.